Marcotte Harold, Piralla Antonio, Zuo Fanglei, Du Likun, Cassaniti Irene, Wan Hui, Kumagai-Braesh Makiko, Andréll Juni, Percivalle Elena, Sammartino Josè Camilla, Wang Yating, Vlachiotis Stelios, Attevall Janine, Bergami Federica, Ferrari Alessandro, Colaneri Marta, Vecchia Marco, Sambo Margherita, Zuccaro Valentina, Asperges Erika, Bruno Raffaele, Oggionni Tiberio, Meloni Federica, Abolhassani Hassan, Bertoglio Federico, Schubert Maren, Calzolai Luigi, Varani Luca, Hust Michael, Xue Yintong, Hammarström Lennart, Baldanti Fausto, Pan-Hammarström Qiang
Department of Biosciences and Nutrition, Karolinska Institutet, Huddinge, Sweden.
Molecular Virology Unit, Microbiology and Virology Department, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
iScience. 2022 Feb 18;25(2):103743. doi: 10.1016/j.isci.2022.103743. Epub 2022 Jan 7.
Information concerning the longevity of immunity to SARS-CoV-2 following natural infection may have considerable implications for durability of immunity induced by vaccines. Here, we monitored the SARS-CoV-2 specific immune response in COVID-19 patients followed up to 15 months after symptoms onset. Following a peak at day 15-28 postinfection, the IgG antibody response and plasma neutralizing titers gradually decreased over time but stabilized after 6 months. Compared to G614, plasma neutralizing titers were more than 8-fold lower against variants Beta, Gamma, and Delta. SARS-CoV-2-specific memory B and T cells persisted in the majority of patients up to 15 months although a significant decrease in specific T cells, but not B cells, was observed between 6 and 15 months. Antiviral specific immunity, especially memory B cells in COVID-19 convalescent patients, is long-lasting, but some variants of concern may at least partially escape the neutralizing activity of plasma antibodies.
关于自然感染后对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)免疫的持久性信息,可能对疫苗诱导的免疫持久性有相当大的影响。在此,我们监测了新冠病毒病(COVID-19)患者在症状出现后长达15个月的SARS-CoV-2特异性免疫反应。在感染后第15 - 28天达到峰值后,IgG抗体反应和血浆中和滴度随时间逐渐下降,但在6个月后稳定下来。与G614相比,血浆中和滴度对贝塔(Beta)、伽马(Gamma)和德尔塔(Delta)变体的降低幅度超过8倍。SARS-CoV-2特异性记忆B细胞和T细胞在大多数患者中持续存在长达15个月,尽管在6至15个月期间观察到特异性T细胞有显著下降,但B细胞没有。抗病毒特异性免疫,尤其是COVID-19康复患者中的记忆B细胞,是持久的,但一些值得关注的变体可能至少部分逃避血浆抗体的中和活性。